Continuing efanesoctocog alfa after earlier trial
Treatments studied
Part of Blood & lymphatic, Cancer, Genetic & congenital, Immune system & allergy clinical trials.
This study provides continued access to the clotting factor treatment efanesoctocog alfa for people who have already been getting it in a previous trial. It helps ensure you can keep using the medicine if it is working for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child have completed one of the earlier studies with efanesoctocog alfa (Sobi.BIVV001-001, Sobi.BIVV001-003, LTS16294, or Sobi.BIVV001-004) and are still benefiting from the treatment.
- You do not have a high level of inhibitors (antibodies that stop the medicine from working).
- You are not taking part in any other clinical trial right now.
- You or your parent/legal representative can give permission (informed consent) and will keep a daily diary.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a preventive treatment called efanesoctocog alfa to see if it can help people with moderate to severe hemophilia A who have joint swelling (synovial hypertrophy). It aims to reduce joint bleeding and improve joint health.
This study looks at how well a medicine called damoctocog alfa pegol (Jivi) works to prevent bleeding in children with hemophilia A. It will follow children who are already using this medicine or starting it, to see how effective it is in real life.
This study tests a new medicine called SKP-0141 to see if it can safely treat and prevent bleeding in people with severe hemophilia A. It might help reduce the number of bleeds and improve quality of life.
This study tests a new treatment (FRSW107) for severe hemophilia A in children under 12. It aims to see if this treatment is safe and helps prevent bleeding episodes.
This study tests a new approach to immune tolerance induction (ITI) in young people with severe hemophilia A who have a high-titer inhibitor. It uses a specific clotting factor combined with emicizumab to try to retrain the immune system so that standard treatments work again.
This study is looking at the safety and effectiveness of a factor VIII medicine called octocog alfa (used to treat bleeding) in men with severe hemophilia A in India. It will track how well the medicine works and any side effects during routine care.
Hear when a new Haemophilia A (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.